# Latigo Biotherapeutics funding rounds and investors

As of 14 Oct 2026, Latigo Biotherapeutics has raised $150M across 1 verified round on record; latest: $150 million Series B led by Blue Owl, announced 17 Mar 2025.

Latigo is a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines.

Website: https://latigobio.com  
Page: https://fireround.dev/companies/latigobio.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-03-17 | Series B | $150 million | Blue Owl | 5AM Ventures, Access Biotechnology, Alexandria Venture Investments, Cormorant Asset Management, Deep Track Capital, Foresite Capital, Kern Capital, Qatar Investment Authority (QIA), Rock Springs Capital, Sanofi Ventures, UPMC Enterprises, Westlake Village BioPartners | [prnewswire.com](https://www.prnewswire.com/news-releases/latigo-biotherapeutics-closes-150-million-in-series-b-financing-to-advance-non-opioid-pain-therapeutics-302397457.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.